This large study from our colleagues in China, show that 20% of women with ovarian insufficiency have genetic changes that explain their disease. It's time to offer genome sequencing to women with this form of infertility. UCSF Obstetrics Gynecology & Reproductive Sciences Nature Medicine nature.com/articles/s4159…

Promising future. #geneediting

Hundreds of trees have fallen in Pebble Beach, Monterey and surrounding areas with our recent storms.

I'm thrilled Adela will be presenting data at #AACR23 showing results of the company's genome-wide methylome enrichment platform to detect cancer. Earlier detection saves lives. The mission-driven team at Adela is doing great work! #earlydetection

linkedin.com/posts/activity…

This is a great advancement in women's health. These new care plans combined with the Mirvie #RNA platform translates risk prediction into disease prevention and reduces complications from #preeclampsia. #PrecisionHealth #PregnancyHealth

It’s an exciting day for #genomics #startups! I am thrilled to be launching Illumina Ventures Labs alongside the Illumina Ventures team to provide #founders with access to #capital, fully equipped genomics labs in the US and UK and support from experienced operators.

Here I sit down with #Illumina's Janina Jeff to share how genetics is being applied in clinical care today and how you may benefit from understanding your genetic insights. Watch here: youtu.be/OKb4ljSKEd8 #genomicmedicine #futureofhealthcare #digitalhealth #changemakers

I'm excited to share ep. 1 of Closing Time is live! Tune in as Lisa Alderson pitches her new startup to Lux Capital General Partner Deena Shakir. Co-hosted with my longtime friend Halle Tecco MBA, MPH, Closing Time gives a unique view into the exciting world of healthcare startups.

This is excellent Halle Tecco MBA, MPH! I recommend this quick read to all entrepreneurs in healthcare.

Loved this! Thanks for hosting me Halle Tecco MBA, MPH and thanks for the great questions Deena Shakir and Michael Esquivel.

resources.genomemedical.com/2023-inc5000

Thank you Slice of Healthcare - "Adela is poised to make significant strides in the realm of early cancer detection and MRD monitoring" sliceofhealthcare.com/adela-inc-secu… #precisionmedicine

Adela will be presenting data at #ESMO23 demonstrating strong prognostic prediction capabilities of our genome-wide methylome enrichment platform in Head and Neck Cancer and Renal Cell Carcinoma adelabio.com/press/adela-pr…

Adela is presenting at #AACR2024! Highlights include data in head & neck cancer from our tissue-agnostic MRD assay, and Chief Scientific Officer Daniel De Carvalho chairing the Plenary Session “Discovery Science in Early Cancer Biology and Interception”. adelabio.com/press/adela-to…

Exciting presentation at ESMO demonstrating Adela's ability to detect recurrence in Head & Neck Cancer patients up to 15 months in advance of imaging/clinical presentation with a mean lead time of 4.1 months. #precisiononcology

Adela demonstrates in a clinical validation study published in The Annals of Oncology the ability to detect recurrence up to 15 months in advance of clinical presentation (mean 4.1 months). Detecting early relapse can contribute to improved outcomes by guiding early intervention.

Jensen Huang, speaking at PMWC to a room full of healthcare pioneers, “Biology is one of the hardest problems. I’ve always hoped that your industry would have the benefit of our industry.” “Artificial intelligence is finding intelligence in the data that you have.”

Heading to Precision Med #TRICON in San Diego? Catch Partner Mara Aspinall at two key sessions: 📅 3/11 | 3:40 PM PT – Driving Innovation in Precision Medicine 📅 3/12 | 8:00 AM PT – Investing in Precision Medicine More info: triconference.com Precision Med TRI-CON

Looking forward to joining Mara Aspinall of Illumina Ventures on stage at #Tricon to discuss how to drive #innovation in precision medicine.